New Age Alpha Advisors LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL)

New Age Alpha Advisors LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 63,149 shares of the biotechnology company’s stock, valued at approximately $2,103,000.

Other hedge funds also recently bought and sold shares of the company. USA Financial Formulas acquired a new stake in shares of Exelixis during the fourth quarter valued at approximately $32,000. Principal Securities Inc. grew its position in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in Exelixis during the 4th quarter valued at $39,000. Brooklyn Investment Group purchased a new stake in shares of Exelixis in the third quarter valued at $42,000. Finally, UMB Bank n.a. boosted its position in shares of Exelixis by 68.4% in the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after buying an additional 553 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Stock Performance

EXEL opened at $36.70 on Friday. The firm has a market cap of $10.27 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The business has a 50 day moving average price of $35.71 and a 200 day moving average price of $33.27. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Exelixis news, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now directly owns 33,514 shares of the company’s stock, valued at $1,248,396.50. The trade was a 35.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last quarter. Insiders own 2.85% of the company’s stock.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Stifel Nicolaus increased their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Royal Bank of Canada boosted their price objective on shares of Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday. Finally, Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and lifted their target price for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.